Ontinuous variables are presented as the

Ontinuous variables are presented as the PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/12711626 mean ?SD and were analyzed by Kolmogorov-Smirnov's test for normality of the distribution and Levene's test for the homogeneity of variance. The variables were compared with Student's t-test for normally distributed variables. For nonnormally distributed variables, the nonparametric Mann?Whitney U-test was used. The frequencies and percentages are given for qualitative variables. Significant differences 1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole were tested by the chi-square test, and Fisher's exact test was used when numbers were too small to perform the chi-square test. Spearman's correlation coefficient was used to determine the relationship between the clinical manifestations, laboratory values, complications and survival outcome, respectively. Binary logistic regression analysis was used to identify clinical risk factors for prognosis. Predicting values for prognosis of the laboratory parameters were tested with receiver operating characteristic (ROC) curves and quantified by calculating the area under the curve (AUC) and the 95 confidence interval (CI). Kaplan-Meier analysis was used for the cumulative proportion surviving and 28-day mortality rate in the critical patients. A twotailed P PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/8711135 had higher frequencies of dyspnea, agitation, conjunctival hemorrhage and coma (P = .049, P .05) (Table 4).HFRS-related complications in the critical patientsOf the HFRS-related complications, the frequencies of cardiac failure, ARDS and encephalopathy in the non-survivors were higher than those in the survivors (P Tert-butyl 2-(chloromethyl)pyrrolidine-1-carboxylate frequencies of pneumonia, arrhythmia,Table 1 Demographic, epidemiologic and clinical characteristics in critical patients with HFRSCharacteristic Demographic characteristics Male/Female, n Mean Age, years Epidemiologic characteristics Career (farmer), n ( ) Incidence (October-December), n ( ) Clinical characteristics Interval from onset to the patient's arrival, days Interval of febrile phase, days Frequency of overlapping hypotensive and oliguric phases, n ( ) Hospital days, daysaSurvivors (n = 46) 37/9 48.76 ?13.Non-survivors P valuea (n = 29) 22/7 53.90 ?11.31 .638 .38 (82.6) 34 (72.3)23 (79.3) 16 (55.2).721 .This retrospective study was reviewed and approved by the Institutional Review Board of Tangdu Hosipital, and the patients' medical records were anonymized and deidentified prior to analysis.6.11 ?6.99 4.84 ?1.68 26 (56.5)4.93 ?2.83 4.64 ?1.37 22 (75.9).391 .595 .ResultsClinical, demographic and epidemiologic conditions of the critical patientsOf the 75 critical patients, 46 survived and 29 died; 59 patients (78.7 ) were male, and 61 patients (81.3 ) were28.35 ?13.7.97 ?12.< .Survivors vs. non-survivors.Du et al. BMC Infectious Diseases 2014, 14:191 http://www.biomedcentral.com/1471-2334/14/Page 4 ofTable 2 Symptoms in critical patients with HFRSSymptoms Dyspnea, n ( ) Fever, n ( ) Nausea, n ( ) Vomiting, n ( ) Anepithymia, n.